ST6Gal1与结直肠癌患者临床病理特征及预后的相关性

doi:10.3760/cma.j.issn.1007-1245.2024.11.025

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (11): 1882-1887.DOI: 10.3760/cma.j.issn.1007-1245.2024.11.025

ST6Gal1与结直肠癌患者临床病理特征及预后的相关性

李德正¹ 段红亮¹ 吴云桦² 魏志力³ 徐玉³

¹陕西省核工业二一五医院普外一病区，咸阳　712000；²陕西省人民医院普外二科，西安　710000；³陕西中医药大学第二附属医院普外肝胆一科，咸阳　712000

收稿日期:2023-03-07 出版日期:2024-06-01 发布日期:2024-06-25
通讯作者: 徐玉，Email：xuyu0906@126.com
基金资助:
陕西省自然科学基础研究计划（2022JQ-763）

Correlation of ST6Gal1 with clinicopathological features and prognosis of patients with colorectal cancer

Li Dezheng¹, Duan Hongliang¹, Wu Yunhua², Wei Zhili³, Xu Yu³

¹First Ward, Department of General Surgery, Shaanxi Nuclear Industry 215 Hospital, Xianyang 712000, China; ²Second Department of General Surgery, Shaanxi Provincial People's Hospital, Xi'an 710000, China; ³First Department of Hepatobiliary Surgery, Second Hospital, Shaanxi University of Chinese Medicine, Xianyang 712000, China

Received:2023-03-07 Online:2024-06-01 Published:2024-06-25
Contact: Xu Yu, Email: xuyu0906@126.com
Supported by:
Basic Research Plan of Natural Science in Shaanxi (2022JQ-763)

摘要/Abstract

摘要：

目的　研究β半乳糖苷α-2，6-唾液酸转移酶1（ST6Gal1）与结直肠癌（CRC）患者临床病理特征及预后的关系。方法　选取2018年12月至2023年6月陕西省核工业二一五医院病理科保存的102例CRC患者术后切除组织及癌旁组织切片。比较不同临床病理特征CRC患者癌组织ST6Gal1阳性率；随访并统计患者预后，将生存患者设为生存组，病死患者设为死亡组；生存组男37例，女25例；年龄≥60岁48例，<60岁25例。死亡组男15例，女16例；年龄≥60岁25例，<60岁6例。采用COX回归模型分析CRC患者预后影响因素；绘制Kaplan-Meier曲线，比较ST6Gal1阳性、阴性表达患者预后，行Log-rank检验。结果　CRC组织ST6Gal1阳性率高于癌旁组织［67.62%（79/102）比13.33%（12/102）；χ²=58.417，P<0.001］。与CRC TNM分期Ⅰ～Ⅱ期［50.00%（17/34）］、腺癌［71.79%（56/78）］、高分化［69.84%（44/63）］、无浆膜浸润［60.00%（21/35）］、无淋巴结转移［62.50%（30/48）］患者比较，CRC TNM分期Ⅲ～Ⅳ期［91.18%（62/68）］、黏液腺癌/印戒细胞癌［95.83%（23/24）］、浆膜浸润［86.57%（58/67）］、中/低分化［89.74%（35/39）］、有淋巴结转移［90.74%（49/54）］患者ST6Gal1阳性率较高（χ²=22.006、6.072、5.463、9.291、11.605，P<0.001、=0.014、=0.019、=0.002、=0.001）。COX回归模型显示，TNM Ⅲ～Ⅳ期、浆膜浸润、肿瘤长径≥5 cm、中/低分化、淋巴结转移及ST6Gal1阳性是CRC患者预后不良的危险因素（均P<0.05）。Log-rank检验显示，ST6Gal1阳性、阴性表达患者Kaplan-Meier曲线差异有统计学意义（χ²=8.578，P=0.003）。结论　CRC组织中ST6Gal1异常高表达，与多种临床病理特征相关，且是CRC患者预后不良的危险因素之一。

关键词:

结直肠癌, β半乳糖苷α-2, 6-唾液酸转移酶1, 临床病理, 预后

Abstract:

Objective　To study the relationship between β-galactoside α-2, 6-sialyltransferase 1 (ST6Gal1) and the clinicopathological characteristics and prognosis of patients colorectal cancer (CRC). Methods　A total of 102 patients with CRC who underwent surgical resection and had tumor and adjacent tissues preserved in Department of Pathology, Shaanxi Nuclear Industry 215 Hospital from December 2018 to June 2023 were selected. The positive rates of ST6Gal1 in the tumor tissues of the patients with different clinicopathological characteristics were compared. The patients were followed up, and their prognosis was recorded. The survival patients were set as a survival group, and the dead patients a death group. There were 37 males and 25 females in the survival group; there were 48 patients who were ≥60 years old and 25 patients who were <60 years old. In the death group, there were 15 males and 16 females; there were 25 cases who were ≥60 years old and 6 cases who were <60 years old. The prognostic factors of the patients with CRC were analyzed by the COX regression model. Kaplan-Meier curves were plotted to compare the prognosis of the patients with positive and negative expression of ST6Gal1, and Log-rank test was performed. Results　The positive rate of ST6Gal1 in the CRC tissue was higher than that in the paracancer tissue [67.62% (79/102) vs. 13.33% (12/102); χ²=58.417, P<0.001]. Compared with those in the patients with CRC TNM stage Ⅰ-Ⅱ [50.00% (17/34)], adenocarcinoma [71.79% (56/78)], highly differentiated CRC [69.84% (44/63)], no serous infiltration [60.00% (21/35)], and no lymph node metastasis [62.50% (30/48)], the positive rates of ST6Gal1 were higher in the patients with TNM stage Ⅲ-Ⅳ [91.18% (62/68)], mucinous adenocarcinoma/sig-ring cell carcinoma [95.83% (23/24)], serous infiltration [86.57% (58/67)], medium/low differentiation [89.74% (35/39)], and lymph node metastasis [90.74% (49/54)] (χ²=22.006, 6.072, 5.463, 9.291, and 11.605; P<0.001, =0.014, =0.019, =0.002, and =0.001). The COX regression model showed that TNM stage Ⅲ-Ⅳ, serosal invasion, tumor diameter ≥5 cm, moderate/low differentiation, lymph node metastasis, and ST6Gal1 positivity were risk factors for poor prognosis of the patients with CRC (all P<0.05). Log-rank test showed that there was a statistical difference in the Kaplan-Meier curves between the patients with positive and negative expressions of ST6Gal1 (χ²=8.578; P=0.003). Conclusion　ST6Gal1 is abnormally highly expressed in CRC tissue, is related to various clinicopathological characteristics, and is one of the risk factors for poor prognosis of patients with CRC.

Key words:

Colorectal cancer, β-galactoside α-2, 6-sialyltransferase 1, Clinicopathology, Prognosis

李德正段红亮吴云桦魏志力徐玉.

ST6Gal1与结直肠癌患者临床病理特征及预后的相关性 [J]. 国际医药卫生导报, 2024, 30(11): 1882-1887.

Li Dezheng, Duan Hongliang, Wu Yunhua, Wei Zhili, Xu Yu.

Correlation of ST6Gal1 with clinicopathological features and prognosis of patients with colorectal cancer [J]. International Medicine and Health Guidance News, 2024, 30(11): 1882-1887.

参考文献

[1] 田若曦,孟泽松,王贵英,等. PD-1/PD-L1抑制剂在结直肠癌治疗中的现状及预后预测[J]. 肿瘤,2020,40(3):215-222. DOI:10.3781/j.issn.1000-7431.2020.55.195.
[2] Chan KM, Hung HC, Lee JC, et al. Individualized selection criteria based on tumor burden in future remnant liver for staged hepatectomy of advanced CRLM: conventional TSH or ALPPS[J]. Cancers (Basel), 2022, 14(14):3553. DOI: 10.3390/cancers14143553.
[3] 刘萍, 骆学新. 肠益方联合XELOX化疗方案对老年晚期结直肠癌患者近期疗效及对血清SDC2、SEPT9和免疫功能的影响[J]. 中国老年学杂志, 2022, 42(5):1085-1087. DOI: 10.3969/j.issn.1005-9202.2022.05.019.
[4] Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1):144. DOI: 10.1186/s12943-022- 01616-7.
[5] Andrade-Meza A, Arias-Romero LE, Armas-López L, et al. Mexican colorectal cancer research consortium (MEX-CCRC): etiology, diagnosis/prognosis, and innovative therapies[J]. Int J Mol Sci, 2023, 24(3):2115. DOI: 10.3390/ijms24032115.
[6] Tufail M. HOTAIR in colorectal cancer: structure, function, and therapeutic potential[J]. Med Oncol, 2023, 40(9):259. DOI: 10.1007/s12032-023-02131-5.
[7] Wang L, Chen X, Wang L, et al. Knockdown of ST6Gal-I expression in human hepatocellular carcinoma cells inhibits their exosome-mediated proliferation- and migration-promoting effects[J]. IUBMB Life, 2021, 73(11):1378-1391. DOI: 10.1002/iub.2562.
[8] Ou L, He X, Liu N, et al. Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance[J]. Mol Med Rep, 2020, 21(3):1449-1460. DOI: 10.3892/mmr.2020.10951.
[9] Venturi G, Gomes Ferreira I, Pucci M, et al. Impact of sialyltransferase ST6GAL1 overexpression on different colon cancer cell types[J]. Glycobiology, 2019, 29(10):684-695. DOI: 10.1093/glycob/cwz053.
[10] Jakubauskas M, Jakubauskiene L, Leber B, et al. Probiotic supplementation suppresses tumor growth in an experimental colorectal cancer liver metastasis model[J]. Int J Mol Sci, 2022, 23(14):7674. DOI: 10.3390/ijms23147674.
[11] Li J, Xu CJ, Tian GA, et al. Spatiotemporal quantification of metastatic tumour cell growth and distribution in lymph nodes by whole-mount tissue 3D imaging[J]. Int J Biol Sci, 2022, 18(10):3993-4005. DOI: 10.7150/ijbs.72552.
[12] 王超, 袁紫旭, 张继业, 等. 结直肠癌患者腹腔镜术后动力性肠梗阻发生现状及影响因素[J].国际医药卫生导报, 2022, 28(16):2221-2224. DOI: 10.3760/cma.j.issn.1007-1245.2022.16.001.
[13] Okamoto T. Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer[J]. World J Gastroenterol, 2022, 28(10):985-1008. DOI: 10.3748/wjg.v28.i10.985.
[14] Kim BJ, Hanna MH. Colorectal cancer in young adults[J]. J Surg Oncol, 2023, 127(8):1247-1251. DOI: 10.1002/jso.27320.
[15] Song M. Global epidemiology and prevention of colorectal cancer[J]. Lancet Gastroenterol Hepatol, 2022, 7(7):588-590. DOI: 10.1016/S2468-1253(22)00089-9.
[16] Borzacchiello L, Veglia Tranchese R, Grillo R, et al. S-adenosylmethionine inhibits colorectal cancer cell migration through mirna-mediated targeting of notch signaling pathway[J]. Int J Mol Sci, 2022, 23(14):7673. DOI: 10.3390/ijms23147673.
[17] Cui H, Yang S, Jiang Y, et al. The glycosyltransferase ST6Gal-I is enriched in cancer stem-like cells in colorectal carcinoma and contributes to their chemo-resistance[J]. Clin Transl Oncol, 2018, 20(9):1175-1184. DOI: 10.1007/s12094-018-1840-5.
[18] Hampel H, Kalady MF, Pearlman R, et al. Hereditary colorectal cancer [J]. Hematol Oncol Clin North Am, 2022, 36(3):429-447. DOI: 10.1016/j.hoc.2022.02.002.
[19] Rao TC, Beggs RR, Ankenbauer KE, et al. ST6Gal-I-mediated sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances invasion[J]. J Biol Chem, 2022, 298(4):101726. DOI: 10.1016/j.jbc.2022.101726.
[20] Zhao J, Yang H, Hu H, et al. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma[J]. Sci Rep, 2022, 12(1):10401. DOI: 10.1038/s41598-022-13997-2.
[21] Liu B, Liu Q, Pan S, et al. The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2/STAT3 cascade[J]. J Exp Clin Cancer Res, 2019, 38(1):455. DOI: 10.1186/s13046-019-1468-5.
[22] Tan T, Hirokawa Y, Clarke J, et al. Low-viscosity matrix suspension culture for human colorectal epithelial organoids and tumoroids[J]. Bio Protoc, 2022, 12(8):e4394. DOI: 10.21769/BioProtoc.4394.
[23] Wang L, Li S, Yu X, et al. α2,6-Sialylation promotes immune escape in hepatocarcinoma cells by regulating T cell functions and CD147/MMP signaling[J]. J Physiol Biochem, 2019, 75(2):199-207. DOI: 10.1007/s13105-019-00674-8.
[24] Watts K, Wills C, Madi A, et al. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome[J]. Int J Cancer, 2022, 151(6):957-966. DOI: 10.1002/ijc.34046.
[25] Yuan Q, Chen X, Han Y, et al. Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway[J]. Int J Cancer, 2018, 143(9):2319-2330. DOI: 10.1002/ijc.31737.

ST6Gal1与结直肠癌患者临床病理特征及预后的相关性

Correlation of ST6Gal1 with clinicopathological features and prognosis of patients with colorectal cancer

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	马利军刘占军韩继明. miR-150-5p、miR-135b在糖尿病肾病患者中的表达及意义 [J]. 国际医药卫生导报, 2024, 30(9): 1454-1459.
[2]	郭江红王欢吴妍. LTBP-2联合心肺联合超声预测老年急性心肌梗死患者短期预后的价值 [J]. 国际医药卫生导报, 2024, 30(8): 1233-1238.
[3]	杨星王秋茹周雪. 脂蛋白a和载脂蛋白B联合维生素D检测对冠心病严重程度及短期预后的评估价值 [J]. 国际医药卫生导报, 2024, 30(8): 1238-1242.
[4]	吴鹏杨鸿炜李朝杰. 经肛门内镜下黏膜剥离术治疗早期直肠癌患者的效果观察 [J]. 国际医药卫生导报, 2024, 30(7): 1181-1185.
[5]	吴媛媛刘科齐艳丽童小华. 非小细胞肺癌组织中CLCA4的表达情况及与病理和预后的关系 [J]. 国际医药卫生导报, 2024, 30(6): 903-907.
[6]	张国坤张天佑张景畅李素新. 原发性肝癌患者TACE预后不良的因素分析：基于PSM法 [J]. 国际医药卫生导报, 2024, 30(5): 747-753.
[7]	王海峰吴照锋侯中玉李亮. 葡萄球菌相关PS患者临床特征及预后分析 [J]. 国际医药卫生导报, 2024, 30(5): 834-838.
[8]	闫荣胡广翠逄红风于杰. 平板运动试验与静息心电图联合评估对冠心病的诊断价值 [J]. 国际医药卫生导报, 2024, 30(4): 619-622.
[9]	刘茗刘帅张楠. 早期乳腺癌患者保乳术后免除放疗的研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 357-362.
[10]	张凯思马金栋张启慧陈强谱. 预康复干预对结直肠癌患者术后临床结局影响的meta分析 [J]. 国际医药卫生导报, 2024, 30(3): 367-373.
[11]	时娟娟杜超李南韩珊珊崔秀娟. 难治性子宫腺肉瘤1例 [J]. 国际医药卫生导报, 2024, 30(3): 503-507.
[12]	崔玉霞杜冰高风双. 慢性疾病轨迹框架下自我护理模式对老年胃癌切除术患者的效果影响 [J]. 国际医药卫生导报, 2024, 30(3): 524-528.
[13]	罗晓洁王巍巍王怡萌王峪. 脓毒症相关急性呼吸窘迫综合征患者28 d死亡的无创预测研究 [J]. 国际医药卫生导报, 2024, 30(2): 263-268.
[14]	王新颖. 硝普钠对高血压危象患者临床体征及预后情况的影响 [J]. 国际医药卫生导报, 2024, 30(2): 284-288.
[15]	姜军选方圆. 补中益气汤在驱动基因阴性NSCLC免疫治疗中的应用价值 [J]. 国际医药卫生导报, 2024, 30(2): 305-309.